<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/rss20.xsl" media="screen"?>
<rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
    <channel>
        <atom:link href="http://xagena.myblog.it/index.rss" rel="self" type="application/rss+xml" />
        <title>Xagena</title>
        <description>Le Novità in Medicina</description>
        <link>http://xagena.myblog.it/</link>
        <lastBuildDate>Sat, 19 May 2012 22:41:07 +0200</lastBuildDate>
        <generator>myblog.it</generator>
        <copyright>All Rights Reserved</copyright>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/05/05/aritmie-news.html</guid>
                <title>Aritmie News</title>
                <link>http://xagena.myblog.it/archive/2012/05/05/aritmie-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 05 May 2012 22:23:58 +0200</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-aritmologia_it_news/cb3e687772d3306c7be2a55580c0dc73.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Una storia di scompenso cardiaco è in grado di predire l’efficacia della terapia antiaritmica&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-aritmologia_it_news/d5215023c7e116864efd4f4965fe6b91.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Ablazione con radiofrequenza della fibrillazione atriale: perforazione esofagea &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-aritmologia_it_news/bcbf5e0ae48ef7e5439863381d1a69bf.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;L'olio di pesce riduce gli interventi del defibrillatore impiantabile per tachicardia ventricolare/fibrillazione ventricolare&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-aritmologia_it_news/a8578be2fe9a67d039ee7b4f18697286.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Defibrillatore impiantabile: debole effetto protettivo dei PUFA omega-3 nei confronti delle aritmie ventricolari &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-aritmologia_it_news/80c7c407281e2ea672696a0147d9fb12.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Donne con disturbi del ritmo: le aritmie prima del parto aumentano il rischio di complicanze avverse fetali&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/05/05/sclerosi-multipla-notizie.html</guid>
                <title>Sclerosi multipla Notizie</title>
                <link>http://xagena.myblog.it/archive/2012/05/05/sclerosi-multipla-notizie.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 05 May 2012 13:14:47 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: xx-large;&quot;&gt;&lt;strong&gt;NEWS Sclerosi multipla&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/index.php?page=5&amp;amp;view=14901&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;La vitamina D interagisce con una variante genetica coinvolta nella sclerosi multipla&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Nella sclerosi multipla, la variazione allelica nella regione MHC ( complesso maggiore di istocompatibilità ) classe II esercita il più forte, singolo, effetto sul rischio genetico.Inoltre, c’è una crescente evidenza riguardo al fatto che la luce solare, o la vitamina D, rappresenti un fattore ambientale chiave nell’eziologia di questa malattia.Ricercatori dell’Uni [...] &lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/index.php?view=14901&amp;amp;page=5&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/index.php?page=9&amp;amp;view=11829&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;L’Interferone-beta ha un impatto negativo sulla qualità di vita dei pazienti con sclerosi multipla&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;L’Interferone beta ( IFN-beta ) mostra effetti benefici sul decorso della sclerosi multipla, tuttavia la sua via di somministrazione, la frequenza di somministrazione e gli effetti indesiderati potrebbero avere un impatto negativo sulla qualità di vita ( QoL ) nei pazienti con sclerosi multipla. Uno studio ha valutato l’influe [...] &lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/index.php?view=11829&amp;amp;page=9&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/index.php?view=18534&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Profilo di sicurezza del trattamento endovascolare per insufficienza venosa cerebrospinale cronica nei pazienti con sclerosi multipla&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;E’ stata valutata la sicurezza del trattamento endovascolare dell’insufficienza venosa cerebrovascolare cronica ( CCSVI ) in pazienti affetti da sclerosi multipla.Nell’arco di 1 anno, 461 pazienti affetti da sclerosi multipla ( 261 donne, età media 45.4 anni, range 21-79 ) con CCSVI sono stati sottoposti a trattamento endovascolare di 1012 lesioni venose durante 495 proced [...] &lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;a href=&quot;http://www.sclerosionline.net/?view=18534&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/05/03/aggiornamenti-in-medicina-video-medicina.html</guid>
                <title>Aggiornamenti in Medicina - Video Medicina</title>
                <link>http://xagena.myblog.it/archive/2012/05/03/aggiornamenti-in-medicina-video-medicina.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Thu, 03 May 2012 01:13:08 +0200</pubDate>
                <description>
                    &lt;div style=&quot;widows: 2; text-transform: none; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/64&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #006666; font-size: medium;&quot;&gt;&lt;strong&gt;La Digossina associata a rischio di cancro al seno&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/63&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;Osteoporosi: Ranelato di Stronzio associato a tossicità cardiovascolare e cutanea&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/62&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;Asma allergico: Omalizumab associato a rischio di eventi trombotici arteriosi&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/61&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;BPCO: Spiriva Respimat associato a più alto rischio di mortalità&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/59&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #6600cc; font-size: medium;&quot;&gt;&lt;strong&gt;Anticoagulanti: valutazione della funzionalità renale nei pazienti in trattamento con Pradaxa&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: small/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;line-height: 17px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 16px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/58&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #6600cc; font-size: medium;&quot;&gt;&lt;strong&gt;Antidiabetici: il Pioglitazone associato a lieve aumento del rischio di tumore della vescica&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;line-height: 17px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 16px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/57&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #6600cc; font-size: medium;&quot;&gt;&lt;strong&gt;Osteoporosi: rischio di insufficienza renale e di mortalità con Acido Zoledronico&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/56&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;Rischio di compromissione dello sviluppo cognitivo nei bambini esposti in utero a prodotti a base di Valproato&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: small/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;line-height: 17px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 16px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/55&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;Strattera associato ad aumento della pressione sanguigna e della frequenza cardiaca&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;line-height: 17px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 16px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/54&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; color: #ff0000; font-size: medium;&quot;&gt;&lt;strong&gt;Multaq associato a un aumento del rischio di gravi eventi cardiovascolari o di mortalità&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/53&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;Rischio cardiovascolare con i farmaci antinfiammatori non-steroidei&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/52&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;Gravi reazioni allergiche con Asenapina, un antipsicotico atipico&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;h3 class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 20px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/51&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;Gravidanza: l'uso cronico di alte dosi dell'antimicotico Fluconazolo è associato a difetti alla nascita&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;ecxvideo-name&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 16px 0px 5px; font: 16px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: small/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/50&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;Melanoma con mutazione BRAF V600E: miglioramento della sopravvivenza con Zelboraf&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: small/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxvideo-meta&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: small/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medtv.it/index/show/id/49&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;Lupus eritematoso sistemico: Benlysta&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/29/video-medicina-oncologia-diabetologia-neurologia-psichiatria.html</guid>
                <title>Video Medicina: oncologia, diabetologia, neurologia, psichiatria</title>
                <link>http://xagena.myblog.it/archive/2012/04/29/video-medicina-oncologia-diabetologia-neurologia-psichiatria.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sun, 29 Apr 2012 01:15:00 +0200</pubDate>
                <description>
                    &lt;h3 class=&quot;video-name&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;ONCOLOGIA&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;&lt;h3 class=&quot;video-name&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/70&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Studio AXIS: confronto tra Axitinib e Sorafenib nel carcinoma a cellule renali metastatico&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h3&gt;&lt;div class=&quot;video-name&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;DIABETOLOGIA&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-name&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/69&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Gravi reazioni di ipersensibilità e pancreatite acuta associate all’uso di Saxagliptin&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;NEUROLOGIA&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/68&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Sclerosi multipla recidivante-remittente: Gilenya e la mortalità per cause cardiache&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;PSICHIATRIA&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/67&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Farmaci che prolungano il QT: Escitalopram, un antidepressivo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;PSICHIATRIA&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;video&quot;&gt;&lt;div class=&quot;video-content&quot;&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.medtv.it/index/show/id/66&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Farmaci che prolungano il QT: Quetiapina, un antipsicotico&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;video-meta&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/23/malattia-di-alzheimer-parte-2.html</guid>
                <title>Malattia di Alzheimer - Parte 2</title>
                <link>http://xagena.myblog.it/archive/2012/04/23/malattia-di-alzheimer-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 23 Apr 2012 02:21:00 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?cat=farmaci&amp;amp;view=18157&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Atorvastatina nella malattia di Alzheimer da moderata a grave&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Sono emerse alcune prove del fatto che le statine potrebbero avere un effetto protettivo e sintomatico nella malattia di Alzheimer.Lo studio randomizzato e controllato LEADe ha valutato l’efficacia e la sicurezza di Atorvastatina ( Torvast ) nei pazienti con malattia in forma moderata-grave.In questo studio internazionale, multicentrico, in doppio-cieco, randomizzat [...] &lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?view=18157&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?cat=farmaci&amp;amp;view=15628&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Donepezil ritarda la progressione a malattia di Alzheimer nei soggetti con decadimento cognitivo lieve e sintomi depressivi&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Ricercatori dell’University of California – Los Angeles ( UCLA ) negli Stati Uniti, hanno condotto uno studio per determinare se la presenza di depressione fosse in grado di predire tassi più alti di progressione della malattia di Alzheimer nei pazienti con anamnesi di decadimento cognitivo lieve e se il trattamento con Doneprezil ( Aricept ) potesse influenzare in modo positivo questa [...] &lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?view=15628&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?cat=farmaci&amp;amp;view=11569&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Farmaci antipsicotici atipici nei pazienti con malattia di Alzheimer&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;I farmaci antipsicotici atipici di seconda generazione sono ampiamente utilizzati nel trattamento della psicosi, dell’aggressività e dell’agitazione nei pazienti con malattia di Alzheimer. Tuttavia, il ruolo di questi farmaci e la loro sicurezza non sono ben definiti. I Ricercatori dello studio CATIE-AD hanno valutato l� [...] &lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a href=&quot;http://www.alzheimeronline.net/index.php?view=11569&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/19/ginecologia-news.html</guid>
                <title>Ginecologia News</title>
                <link>http://xagena.myblog.it/archive/2012/04/19/ginecologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Thu, 19 Apr 2012 00:30:57 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncoginecologia.net/index.php?page=2&amp;amp;view=17795&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;La densità mammaria in mammografia rappresenta un fattore di rischio per il tumore alla mammella nelle donne con mutazioni BRCA ?&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;L'aumento della densità mammaria in mammografia è un fattore di rischio riconosciuto per il carcinoma mammario nella popolazione generale, tuttavia non è chiaro se rappresenti un fattore di rischio nelle donne con mutazioni BRCA.Uno studio di screening caso-controllo ha valutato la relazione tra densità mammaria e l’incidenza di tumore mammario in questa popolazione. [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.oncoginecologia.net/index.php?view=17795&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?cat=farmaci&amp;amp;view=18221&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Venlafaxina versus Gabapentin per il trattamento delle vampate di calore in donne sopravvissute a carcinoma mammario&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Gli interventi farmacologici non-ormonali sono raccomandati nel trattamento delle vampate di calore in persone sopravvissute a tumore mammario.È stato dimostrato che gli antidepressivi e Gabapentin sono entrambi efficaci e ben tollerati, ma, tuttavia, non è chiaro quale delle due categorie di farmaci sia da preferire.È stato condotto uno studio a gruppi sequenziali [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/?view=18221&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medicinadonna.it/index.php?page=16&amp;amp;view=59&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Ipertensione in gravidanza&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;È un segno frequente, ed è associato ad un aumento della morbilità e della mortalità materna e fetale. Le ipertensioni in gravidanza si classificano in: ipertensione e /o proteinuria gestazionale - Si verifica durante la gravidanza, travaglio o puerperio, in assenza di ipertensione/proteinuria precedenti la gravidanza. L’associazione contemporanea di ipertens [...]&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.medicinadonna.it/index.php?view=59&amp;amp;page=16&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;&lt;strong&gt;Leggi articolo completo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/16/urologia-news-parte-2.html</guid>
                <title>Urologia News - Parte 2</title>
                <link>http://xagena.myblog.it/archive/2012/04/16/urologia-news-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 16 Apr 2012 00:29:00 +0200</pubDate>
                <description>
                    &lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?view=18403&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Profili di rischio e modelli di trattamento nella terapia del tumore alla prostata con un livello di antigene prostatico specifico inferiore a 4 ng/mL&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Nonostante la controversia sul vantaggio di uno screening per l’antigene prostatico specifico ( PSA ), poco si sa sui profili di rischio e i modelli di trattamento negli uomini diagnosticati con tumore alla prostata, con un valore di antigene prostatico specifico inferiore o uguale a 4 ng/mL.Lo studio ha preso in esame i dati del registro SEER ( Surveillance, Epidemiology, and [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18403&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?cat=farmaci&amp;amp;view=18330&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Radioterapia con concomitante Carbogeno e Nicotinamide nel carcinoma della vescica&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Studi clinici di fase II hanno indicato che modificazioni ipossiche con Carbogeno e Nicotinamide potrebbero aumentare l'efficacia della radioterapia.Uno studio ha coinvolto 333 pazienti con carcinoma della vescica localmente avanzato che sono stati assegnati in maniera casuale a radioterapia da sola versus radioterapia con Carbogeno e Nicotinamide.Sono stati utilizzat [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18330&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt; &lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;strong&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?view=18226&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Impatto della terapia di deprivazione androgenica sulla funzione fisica e qualità di vita negli uomini con carcinoma prostatico non-metastatico&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Uno studio prospettico longitudinale ha valutato l’effetto della terapia di deprivazione androgenica sulla funzione fisica oggettiva e auto-riferita.Sono stati arruolati in questo studio di coorte uomini con tumore alla prostata non-metastatico che stavano iniziando una terapia di deprivazione androgenica continua.La funzione fisica è stata valutata con test del ca [...] &lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18226&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/16/urologia-news-parte-1.html</guid>
                <title>Urologia News - Parte 1</title>
                <link>http://xagena.myblog.it/archive/2012/04/16/urologia-news-parte-1.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 16 Apr 2012 00:23:48 +0200</pubDate>
                <description>
                    &lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?view=18325&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Impatto delle comuni terapie sui livelli sierici totali di antigene prostatico specifico &lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Studi precedenti hanno indicato che alcune comuni terapie possono alterare i livelli di antigene prostatico specifico ( PSA ), ma resta poco chiaro se effetti legati ai farmaci siano legati a fattori clinico-demografici o all’uso concomitante di altri farmaci.Uno stuio ha valutato l’impatto di terapie comuni, da sole o in combinazione, sui livelli di PSA in un ampio studio cr [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18325&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt; &lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?cat=farmaci&amp;amp;view=18161&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Immunoterapia con vaccini poxvirali modulata in base al PSA nel carcinoma prostatico metastatico resistente a castrazione&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;I vaccini terapeutici poxvirali basati sul PSA ( antigene prostatico specifico ) per il carcinoma della prostata sono risultati ben tollerati.Uno studio randomizzato, controllato e in cieco, di fase 2, ha valutato il trattamento con PROSTVAC-VF in termini di sicurezza e di prolungamento di sopravvivenza libera da progressione e sopravvivenza generale.In totale, 125 pa [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18161&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;div class=&quot;post&quot;&gt;&lt;h2 class=&quot;post-title&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/index.php?cat=farmaci&amp;amp;view=18129&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;font-family: Arial;&quot;&gt;Abiraterone più Prednisone nei pazienti con carcinoma prostatico resistente a castrazione, trattati con Docetaxel&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;post-content&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Nei carcinomi prostatici resistenti a castrazione è stata documentata la persistenza della via di segnalazione del recettore dell’androgeno mediata da ligando.Abiraterone acetato è un inibitore potente e selettivo di CYP17, che è richiesto per la biosintesi di androgeno in testicoli, ghiandole surrenali e tessuto prostatico.Uno studio ha valutato l’efficacia e [...] &lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;post-more&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a href=&quot;http://www.urologiaonline.net/?view=18129&amp;amp;page=1&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;post-more&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-d.html</guid>
                <title>Farmaci Notizie - Parte D</title>
                <link>http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-d.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 10 Apr 2012 17:21:35 +0200</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/5c0c3007f1af27e1191082e12a27b0b8.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Anziani: rischio di infarto del miocardio subito dopo l'assunzione di Vioxx, un inibitore selettivo Cox-2&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/967162a0b2dc0483ad3d0f47dfb1e9ac.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Januvia nel trattamento dei pazienti con diabete mellito di tipo 2&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/01baf76735e53fba2b533ad071288344.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Naltrexone a rilascio prolungato nel trattamento dei pazienti con dipendenza da alcol&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/11997aab46c754fb90f36b9d8e4eaf99.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Galvus nel trattamento dei pazienti con diabete mellito di tipo 2&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/e7a29a17f7144e9bf52932fc7c6f9f92.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Farmaci per il diabete mellito: mancano studi di sicurezza nel lungo periodo riguardo l'Insulina per via inalatoria&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-c.html</guid>
                <title>Farmaci Notizie - Parte C</title>
                <link>http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-c.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 10 Apr 2012 17:16:39 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/eb61c2b1b1bf5d25c86da9fceef54538.html&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Cymbalta nel trattamento della neuropatia diabetica&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/a2b834e585967887c4522fa09f0b6395.html&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Lenalidomide nel trattamento dell'anemia dipendente dalle trasfusioni, dovuta a sindromi mielodisplastiche a basso rischio o intermedio, associate a delezione 5q&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/8a2bd3e7515b99c88006a6956bc284e9.html&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Farmaci anticonvulsivanti: Topamax nel trattamento dell'epilessia, sindrome di Lennox-Gastaut, e dell'emicrania&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/9bdef7d91f7c5a618c769110e712745b.html&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Exemestane come terapia adiuvante del cancro alla mammella in fase precoce nelle donne in post-menopausa&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/2638f62232521dd30dc5bf604a6d23e4.html&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Ipertensione arteriosa polmonare: Tracleer&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-b.html</guid>
                <title>Farmaci Notizie - Parte B</title>
                <link>http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-b.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 10 Apr 2012 17:10:39 +0200</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/133fb38e53d861f95008113cca0fefbe.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Sutent nel trattamento del tumore a cellule renali avanzato e dei tumori stromali gastrointestinali &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/1d1f05e59ddfa82248f422b49a72c2b3.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Rituximab nel trattamento dei pazienti con forma refrattaria dell’artrite reumatoide &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/54591b5c8d4291c395119bdbdb3a4ee9.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Tosse acuta e cronica: lineeguida ACCP &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/ab7c2d6f143b42faf360c6b52fcc2f05.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Anziani: Tequin associato ad alterazioni della glicemia&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/871f70868dc7160a8e1f2d5e076fe144.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Cetuximab nel trattamento del cancro della testa e del collo &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-a.html</guid>
                <title>Farmaci Notizie - Parte A</title>
                <link>http://xagena.myblog.it/archive/2012/04/10/farmaci-notizie-parte-a.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 10 Apr 2012 17:05:50 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/a65eb348fb03103dcd48530b52b996a7.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Rischio cardiovascolare per i pazienti che impiegno con frequenza il Paracetamolo e i FANS&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/3a78f1864ab77dbd239fbe33cae90bbb.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Ranolazina nel trattamento dell’angina pectoris cronica&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/f8218cc7aea3923da3fab72d435544c0.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Disturbo bipolare: non c'è sufficiente evidenza per raccomandare l’impiego di Topamax&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/e87152a7cbeb2c3262d51598e1de52d5.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Pradif: controindicazioni all’impiego ed effetti indesiderati&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmaci.xagena.it/388ac20c845a327f97edece8acba6237.html&quot;&gt;&lt;span style=&quot;color: #008000; font-size: large;&quot;&gt;&lt;strong&gt;Rischio di NAION con gli inibitori della fosfodiesterasi di tipo 5, farmaci impiegati nel trattamento della disfunzione erettile &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/10/farmacosorveglianza-news-parte-2.html</guid>
                <title>Farmacosorveglianza News - Parte 2</title>
                <link>http://xagena.myblog.it/archive/2012/04/10/farmacosorveglianza-news-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 10 Apr 2012 10:39:06 +0200</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/7dc18693b9385d133160f80154c8976d.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Infezioni batteriche: Tavanic può causare disturbi epatici e disglicemia &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/a8e0614f304631badb289376e7354d33.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;I farmaci per ADHD associati a eventi avversi psichiatrici e cardiovascolari &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/2806c23dbff477d1a3911b012d7db02a.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Asma allergica: Omalizumab può causare anafilassi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/96fb9b48825b741083d35b0137af1be0.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Le donne diabetiche trattate con il glitazone Avandia a rischio di fratture &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/3124d54782a73b7c46fdbbb167b00f2c.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Ranibizumab, un farmaco per la degenerazione maculare senile umida, è associato a insorgenza di ictus&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/09/farmacosorveglianza-news.html</guid>
                <title>Farmacosorveglianza News - Parte 1</title>
                <link>http://xagena.myblog.it/archive/2012/04/09/farmacosorveglianza-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 09 Apr 2012 22:25:00 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/b1491b673670aeae2dbf8827ba87a758.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Un bambino è morto dopo aver assunto in modo accidentale un sovradosaggio della combinazione Lopinavir e Ritonavir &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/916c389b30d9307cfa88f78e037eed17.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Antiepilettici: Depakin associato a difetti del campo visivo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/18dabb99ce171ea5a317521425d5c206.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Gravi problemi oculari con l'impiego off-label di Triamcinolone acetonide&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/bf34e4c28fa03210f476777d37953134.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Malattia di Kawasaki associata al vaccino per la prevenzione dell'infezione da rotavirus, RotaTeq&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;a href=&quot;http://farmacovigilanza.xagena.it/07be74f1a1b5e0a89a5f78ce1725a7eb.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Antidepressivi: discrasie ematiche con Remeron&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/08/notizie-su-sclerosi-multipla.html</guid>
                <title>Notizie su Sclerosi multipla</title>
                <link>http://xagena.myblog.it/archive/2012/04/08/notizie-su-sclerosi-multipla.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sun, 08 Apr 2012 22:12:28 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-sclerosimultipla_it_farmaci/30f607dcab85f4577f6935084e733fd2.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Somministrazione accidentale di un alto dosaggio di Endoxan e remissione di lungo periodo della sclerosi multipla&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-sclerosimultipla_it_farmaci/d93c96e6a23fff65b91b900aaa541998.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Avonex riduce l’atrofia cerebrale nella sclerosi multipla recidivante-remittente&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-sclerosimultipla_it_farmaci/ed1d136ff42ccec596038ba1c11c8a46.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Sclerosi multipla recidivante: Laquinimod riduce lo sviluppo di lesioni attive alla risonanza magnetica per immagini&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-sclerosimultipla_it_farmaci/f75dddd1e79826a219cb0bec217dc096.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Avonex e Tysabri in combinazione per il trattamento della sclerosi multipla recidivante-remittente &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-sclerosimultipla_it_farmaci/f4fce05b7e6af04c39a65a97418bb529.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Sclerosi multipla recidivante: Fingolimod, benefici a 1 anno&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/08/informazioni-su-neurologia.html</guid>
                <title>Informazioni su Neurologia</title>
                <link>http://xagena.myblog.it/archive/2012/04/08/informazioni-su-neurologia.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sun, 08 Apr 2012 20:38:51 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/82ca5dd156cc926b2992f73c2896f761.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff00ff; font-size: large;&quot;&gt;&lt;strong&gt;Il trattamento con Aricept produce benefici solo di breve durata nel decadimento cognitivo lieve&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/6be93f7a96fed60c477d30ae1de032fd.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff00ff; font-size: large;&quot;&gt;&lt;strong&gt;Malattia di Parkinson: il Coenzima Q10 sembra rallentare il deterioramento progressivo funzionale &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/9407c826d8e3c07ad37cb2d13d1cb641.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff00ff; font-size: large;&quot;&gt;&lt;strong&gt;Candesartan: un farmaco antipertensivo nella prevenzione dell'emicrania senza aura&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/0d7363894acdee742caf7fe4e97c4d49.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff00ff; font-size: large;&quot;&gt;&lt;strong&gt;Sclerosi multipla: Tysabri riduce il numero delle lesioni infiammatorie cerebrali e diminuisce le recidive &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-neurologia_it_farmaci/0747b9be4f90056c30eb5241f06bfe9b.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff00ff; font-size: large;&quot;&gt;&lt;strong&gt;Aricept nel trattamento della demenza vascolare&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/08/notizie-su-asma.html</guid>
                <title>Notizie su Asma</title>
                <link>http://xagena.myblog.it/archive/2012/04/08/notizie-su-asma.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sun, 08 Apr 2012 19:51:16 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;a href=&quot;http://asma.xagena.it/farmaci/9f17b99429db7fc2b140436638ae4805.html&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Il Montelukast aumenta la percentuale di fallimento della terapia nei pazienti con asma&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;a href=&quot;http://asma.xagena.it/farmaci/54eb551059f626c9e2682813fff354a8.html&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Benefici del trattamento con bassi dosaggi di Budesonide nei pazienti con asma persistente di recente insorgenza&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;a href=&quot;http://asma.xagena.it/farmaci/7515989d1c2f94c0cf8c5e4aefd3d12b.html&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Asma: effetti sull’infiammazione bronchiale del Salmeterolo aggiunto ai corticosteroidi&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;a href=&quot;http://asma.xagena.it/farmaci/492284833481ed2fd377c50abdedf9f1.html&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Efficacia dell’Omalizumab nelle esacerbazioni d’asma nei pazienti con asma persistente grave&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;a href=&quot;http://asma.xagena.it/farmaci/dfccdb8b1cc7e4dab6d33db0fef12b88.html&quot;&gt;&lt;span style=&quot;color: #008000;&quot;&gt;&lt;span style=&quot;font-family: Arial; font-size: large;&quot;&gt;&lt;strong&gt;Effetti dei corticosteroidi inalati sui leucotrieni e sui prostanoidi esalati nei bambini asmatici&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/07/farmacovigilanza-news.html</guid>
                <title>Farmacovigilanza News</title>
                <link>http://xagena.myblog.it/archive/2012/04/07/farmacovigilanza-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 07 Apr 2012 22:25:54 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmacovigilanza_it_news/632e701d45bdd7eab08afe74d6bd1534.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Farmaci antinfluenzali: morte di un paziente trattato Zanamivir polvere per inalazione&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmacovigilanza_it_news/bcc226682d1d98b133661163114ba831.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Corticosteroidi: gravi reazioni avverse oculari dopo somministrazione del Triamcinolone acetonide per iniezione intravitreale &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmacovigilanza_it_news/40a115d736494ae0bf5b6b65c715868d.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Aumentato rischio di osteonecrosi della mandibola nei pazienti trattati con bifosfonati&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmacovigilanza_it_news/4ff5d86ae9f50c4254668fedafa137ca.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Exenatide può causare alterazione della funzione renale nei pazienti con diabete di tipo 2&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmacovigilanza_it_news/68722b092586cf1d41e07bb366c760c6.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Antibiotici: macrolidi e fluorochinoloni possono causare aritmie ventricolari e arresto cardiaco &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/05/malattie-tiroidee-news.html</guid>
                <title>Malattie tiroidee News</title>
                <link>http://xagena.myblog.it/archive/2012/04/05/malattie-tiroidee-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Thu, 05 Apr 2012 01:34:27 +0200</pubDate>
                <description>
                    &lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: x-large;&quot;&gt;&lt;span style=&quot;line-height: normal; font-size: x-large;&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 41px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 41px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/index.php?view=16352&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Amiodarone e tiroide&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;E’ raccomandata la valutazione dei valori di TSH e degli anticorpi anti-TPO ( anticorpi anti-tireoperossidasi ) prima di iniziare il trattamento con Amiodarone ( Cordarone ).L’utilità di misurazioni periodiche di TSH ( ormone stimolante la tiroide ), ogni 6 mesi, durante terapia con Amiodarone è limitata dall’insorgenza improvvisa di tireotossicosi indotta dall’antiarit [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/?view=16352&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/index.php?view=15166&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Malattia di Graves: danno epatico con il Propiltiouracile&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’FDA ha lanciato un alert sul rischio di grave danno epatico, tra cui insufficienza epatica e morte, con l’uso di Propiltiouracile ( un farmaco non in vendita in Italia ) nei pazienti adulti e pediatrici.L’Agenzia statunitense per il controllo dei farmaci ha identificato nel sistema AERS ( Adverse Event Reporting System ) 32 casi ( 22 pazienti adulti e 10 pazienti pediatri [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/?view=15166&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/index.php?view=14333&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Malattia di Graves: la tiroidectomia subtotale endoscopica in casi selezionati&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Ricercatori dell’Iwate Medical University a Morioka in Giappone hanno valutato la fattibilità e gli outcome ( esiti ) della tiroidectomia subtotale endoscopica per la malattia di Graves.Dal 1998 al 2008, un totale di 100 pazienti con malattia tiroidea benigna sono stati sottoposti a tiroidectomia endoscopica mediante l’approccio mammario.Per 42 di questi pazienti la ti [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.tiroidologia.net/?view=14333&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/04/farmaci-potenzialmente-pericolosi-parte-2.html</guid>
                <title>Farmaci potenzialmente pericolosi - Parte 2</title>
                <link>http://xagena.myblog.it/archive/2012/04/04/farmaci-potenzialmente-pericolosi-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Wed, 04 Apr 2012 01:12:27 +0200</pubDate>
                <description>
                    &lt;p style=&quot;widows: 2; text-transform: none; text-indent: 0px; margin: 0px 0px 1.35em; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: arial, helvetica, sans-serif; font-size: xx-large;&quot;&gt;&lt;strong style=&quot;line-height: 62px; font-weight: bold;&quot;&gt;News&lt;span class=&quot;Apple-converted-space&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;span style=&quot;line-height: normal; background-color: #ff0000; color: #ffffff;&quot;&gt;&amp;gt;&lt;/span&gt;&amp;nbsp;Farmaci potenzialmente pericolosi&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/index.php?view=15760&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Rischio epatotossicità con Voltaren gel&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Novartis ha informato riguardo a gravi reazioni epatiche dopo applicazione del farmaco Voltaren gel.Voltaren gel è un preparato ad azione antinfiammatoria, che trova indicazione nel sollievo del dolore da osteoartrosi a livello delle ginocchia e delle mani, mediante un trattamento topico.Voltaren non è stato valutato per l’impiego delle articolazioni a livello della col [...]&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/?view=15760&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/index.php?view=18521&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Ketoprofene per uso topico e rischio di reazioni di fotosensibilizzazione&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Il Comitato per i Medicinali per Uso Umano ( CHMP ) dell’EMA ( European Medicines Agency ) ha condotto nel 2010 una revisione scientifica dei dati di sicurezza e di efficacia dei medicinali contenenti Ketoprofene per uso topico, a seguito delle segnalazioni di reazioni avverse di fotosensibilizzazione e di co-sensibilizzazione con l’Octocrilene ( filtro UV ).Il CHMP ha concluso che [...]&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/?view=18521&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/index.php?view=12835&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Gardasil: dati di sicurezza dal database VAERS&lt;/span&gt;&lt;/a&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La sicurezza del vaccino Gardasil non è ancora ben definita.Le informazioni contenute nel database VAERS ( Vaccine Adverse Reporting System ) fanno ipotizzare che il vaccino quadrivalente ( HPV4 ) sia associato anche ad eventi avversi gravi.Il sistema VAERS è un’iniziativa dei CDC ( Cennters for Disease Control and Prevention ) e dell’FDA ( Food and Drug Administra [...]&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.farmacovigilanza.net/?view=12835&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/04/03/farmacia-news-parte-1.html</guid>
                <title>Farmacia News - Parte 1</title>
                <link>http://xagena.myblog.it/archive/2012/04/03/farmacia-news-parte-1.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Tue, 03 Apr 2012 01:18:46 +0200</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacia.xagena.it/c703c1c23ad683836fe8c1acce9b850a.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Norlevo nella contraccezione d’emergenza&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacia.xagena.it/4d9b45c6f8d4b9d814b0ca849a6c6dda.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Mifegyne nell’interruzione della gravidanza&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacia.xagena.it/f76cb028c8ecffba608227be898f41a8.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Ipocolesterolemizzanti: l’FDA ha aperto un’inchiesta sul possibile rischio di tumore con Inegy&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacia.xagena.it/94febc12ef3e7fc6326a0a43d4f930c5.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Emicrania: trattamento profilattico&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;a href=&quot;http://farmacia.xagena.it/911ab169c2439cbc201acc1e13d557eb.html&quot;&gt;&lt;span style=&quot;font-family: Arial; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;I bifosfonati possono causare osteonecrosi della mandibola nei pazienti con osteoporosi&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/24/aggiornamenti-in-ginecologia.html</guid>
                <title>Aggiornamenti in Ginecologia</title>
                <link>http://xagena.myblog.it/archive/2012/03/24/aggiornamenti-in-ginecologia.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sun, 25 Mar 2012 00:00:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: xx-large;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: x-small;&quot;&gt;News Ginecologia&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17306&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Isterectomia laparoscopica per malattia benigna: valutazione e complicazioni rispetto alle procedure vaginali e addominali&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Un gruppo di Ricercatori dell’Università Cattolica di Lovanio in Belgio, ha condotto uno studio per valutare il tasso di complicazioni dopo isterectomia laparoscopica totale e subtotale in caso di malattia benigna.Tra le 4505 isterectomie effettuate dalla stessa equipe utilizzando le stesse tecniche nel periodo compreso tra il 1990 e il 2006, 3190 sono state effettuate in lapa [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17306&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17303&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Sacrocolpopessia laparoscopica per il trattamento del prolasso degli organi pelvici&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I Ricercatori del St Mary's Hospital a Manchester nel Regno Unito, hanno portato a termine uno studio osservazionale prospettico su donne che dovevano sottoporsi a sacrocolpopessia laparoscopica per prolasso con lo scopo di valutare l’esito a 2 anni di questa procedura.Sono state arruolate 22 donne che prendevano parte a uno studio longitudinale prospettico sul prolasso e sotto [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17303&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17294&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Coinvolgimento parametriale in campioni di isterectomia radicale in donne con tumore della cervice di stadio precoce&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I Ricercatori del MD Anderson Cancer Center di Houston, negli Stati Uniti, hanno condotto uno studio per stimare l’incidenza del coinvolgimento parametriale e per valutare i fattori associati alla diffusione parametriale in donne con cancro della cervice allo stadio iniziale e per identificare una coorte di pazienti a basso rischio che potrebbero beneficiare di un intervento chirurgico men [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17294&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17239&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Il menarca in giovane età è associato a malattia cardiovascolare e mortalità per cause cardiovascolari&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La relazione tra età al menarca e malattia cardiovascolare non è ancora ben definita.Due recenti studi hanno mostrato un’associazione inversa tra età al menarca e mortalità per tutte le cause.Un gruppo di Ricercatori dell’University Cambridge, nel Regno Unito, ha portato a termine uno studio prospettico di popolazione per esaminare la relazione tra età al menarca e [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17239&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17219&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Ooforectomia o conservazione delle ovaie al momento dell’isterectomia ed esiti di salute nel lungo periodo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Un gruppo di Ricercatori del Saint John's Health Center, a Santa Monica negli Stati Uniti, ha esaminato gli esiti a lungo termine sulla salute e la mortalità dopo ooforectomia o conservazione ovarica.Lo studio prospettico, osservazionale, ha riguardato 29.380 donne partecipanti al Nurses' Health Study sottoposte a isterectomia per patologia benigna; 16.345 ( 55.6% ) sono state s [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17219&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?page=3&amp;amp;view=17204&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Effetti della terapia parodontale sul tasso di parti pre-termine&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Sono stati valutati gli effetti del trattamento della malattia parodontale materna sull’incidenza di parti prematuri ( nati prima delle 37 settimane di gestazione ).Il Maternal Oral Therapy to Reduce Obstetric Risk Study è uno studio randomizzato e controllato su donne incinte con malattia parodontale che stavano ricevendo assistenza ostetrica standard.Le partecipa [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologia.net/index.php?view=17204&amp;amp;page=3&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/index.php?view=17929&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Avastin nel trattamento del carcinoma mammario metastatico&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Il CHMP ( Committee for Medicinal Products for Human Use ) dell’EMA ( European Medicine Agency ) ha raccomandato che Avastin ( Bevacizumab ), quando utilizzato per trattare il tumore alla mammella metastatico, deve essere usato solo in combinazione con il taxano Paclitaxel. Ciò fa seguito ad una revisione relativa all’uso di Avastin in combinazione con i taxani dove il Comitato ha concl [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/?view=17929&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/index.php?view=17924&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Raccomandazione WGP sull’esposizione in utero ai farmaci antidepressivi&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;E’ stato segnalato nella rete nazionale di Farmacovigilanza un caso di sindrome da astinenza neonatale insorta nelle prime ore di vita in un bambino esposto in utero a Paroxetina ( Eutimil, Seroxat, Sereupin ) ed Olanzapina ( Zyprexa ) per uno stato depressivo della madre. In particolare alla nascita il bambino, nato da parto distocico con applicazione di ventosa, presentava un quadro di s [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/?view=17924&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/index.php?view=17749&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; color: #ff0000; text-decoration: underline;&quot;&gt;Sopravvivenza libera da eventi: nessuna differenza tra Exemestane e Anastrozolo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Non è stata riscontrata una differenza significativa tra due inibitori dell'aromatasi riguardo alla sopravvivenza libera da eventi in uno studio che ha messo a confronto questi farmaci nel tumore iniziale della mammella.Dopo un periodo di follow-up mediano di 4.1 anni, le pazienti trattate con Exemestane ( Aromasin ) hanno presentato un tasso di sopravvivenza libera da eventi de [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; font-size: medium;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.ginecologiaonline.net/?view=17749&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/21/neurologia-news.html</guid>
                <title>Neurologia News</title>
                <link>http://xagena.myblog.it/archive/2012/03/21/neurologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Wed, 21 Mar 2012 00:38:57 +0100</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/index.php?view=17554&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Studio CLOSURE I: nessuna riduzione dell’incidenza di ictus o TIA con la chiusura del forame ovale pervio&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I risultati finali dello studio CLOSURE I, randomizzato e controllato, non hanno evidenziato benefici dalla chiusura del forame ovale pervio ( PFO ) riguardo a TIA ( attacco ischemico transitorio ) o ictus a 2 anni, mortalità per tutte le cause a 30 giorni, e mortalità neurologica tra 31 giorni e 2 anni.Hanno preso parte allo studio CLOSURE I 909 pazienti, assegnati in modo cas [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/?view=17554&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/index.php?view=17331&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Alcuni farmaci anticonvulsivanti associati a comportamento suicidario e ad autolesionismo&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Uno studio, pubblicato su Neurology, ha mostrato che alcuni farmaci per l’epilessia sono associati a un aumento del rischio di pensieri e comportamenti suicidari.Nel 2008, l'FDA ( Food and Drug Administration ) ha emesso un alert sui vecchi e sui nuovi farmaci antiepilettici dopo che una ricerca svolta dall’Agenzia stessa aveva trovato una relazione tra l’uso di questi farm [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/?view=17331&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/index.php?view=17094&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;color: #ff0000; text-decoration: underline;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Approvato dall’FDA Gilenya, il primo farmaco per os che ha dimostrato di ridurre le ricadute e di rallentare la progressione della disabilità nella sclerosi multipla&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’FDA ( Food and Drug Administration ) ha approvato Fingolimod ( Gilenya ), terapia orale per la sclerosi multipla , al dosaggio giornaliero di 0.5 mg, come terapia di prima linea per le forme recidivanti di sclerosi multipla, la forma più frequente della malattia.L'autorizzazione dell’ FDA fa di Fingolimod il primo trattamento orale disponibile negli Stati Uniti per le forme reci [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologiaonline.net/?view=17094&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/19/ematologia-news-parte-2.html</guid>
                <title>Ematologia News - Parte 2</title>
                <link>http://xagena.myblog.it/archive/2012/03/19/ematologia-news-parte-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 19 Mar 2012 01:00:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/007f1041969194e99b73e4e5fac7396f.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Linfoma angioimmunoblastico a cellule T: il trapianto allogenico di cellule staminali è in grado di indurre remissioni a lungo termine &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/964e7520947a0d3ac39504daea604d83.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Leucemia mielocitica acuta: incidenza più elevata di recidiva con le cellule staminali da sangue periferico che con quelle di midollo osseo nei pazienti adulti &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/eecd2755d73701aa057cd2a32bd7b1e2.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;color: #0000ff; font-size: large;&quot;&gt;&lt;strong&gt;Ridotta funzione sessuale per gli uomini sopravvissuti a linfoma &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/c7518a1b6d7dfba75ad2cc2fc526fa65.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Leucemia promielocitica acuta con alta conta leucocitaria: miglioramento degli esiti negli ultimi 15 anni&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif; color: #0000ff;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/95c1c113cb2941a27c0404300b58afbf.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;Pazienti sopravvissuti a linfoma di Hodgkin: aumentato rischio di attacco ischemico transitorio e di ictus &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/19/ematologia-news-parte-1.html</guid>
                <title>Ematologia News - Parte 1</title>
                <link>http://xagena.myblog.it/archive/2012/03/19/ematologia-news-parte-1.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Mon, 19 Mar 2012 00:52:00 +0100</pubDate>
                <description>
                    &lt;div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/3af7f46272a016915551cac327041001.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Il trattamento prolungato con Glivec ha promosso la formazione ossea &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/6563f4cdc1f2ef1ad710ad6772ea022b.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Miglioramenti della sopravvivenza con le nuove terapie nei pazienti con mieloma multiplo&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/48e4527085f884352825f9f7df2846db.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Relazione tra linfocitosi monoclonale delle cellule B e leucemia linfocitica cronica &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/e860392d1fe54c1c4a37f46e2ed359fb.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Prognosi sfavorevole per il linfoma primitivo cutaneo diffuso a grandi cellule B delle gambe&lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;font-family: arial,helvetica,sans-serif;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-ematologia_it_news/68cc84f0834098558e316e76dc5d8c7b.html&quot;&gt;&lt;span style=&quot;color: #ff0000; font-size: large;&quot;&gt;&lt;strong&gt;Sindrome mielodisplastica e leucemia mielogena acuta associate a radioimmunoterapia con Zevalin nel linfoma non-Hodgkin &lt;/strong&gt;&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/17/medicina-news-4.html</guid>
                <title>Medicina News (4)</title>
                <link>http://xagena.myblog.it/archive/2012/03/17/medicina-news-4.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 17 Mar 2012 21:43:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_farmaci/92876ef2d2fb0dc247ca63781726025c.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Deltarinolo nel trattamento dell'ostruzione nasale provocata da riniti, sinusiti e rinofaringiti&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_farmaci/d97dfe4d6bab44f304da189cdcb5bc74.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Aspirina nel trattamento delle malattie reumatiche e muscoloscheletriche&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_farmaci/0412057393e8a45b3ba8b16874b6034d.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Postmenopausa e cancro al seno trattato con Femara: prevenzione della perdita ossea con Zometa&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_farmaci/2478f263ea867250ce8fcbfd57c06fe4.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Xarelto più efficace di Clexane nella tromboprofilassi dopo artroplastica totale del ginocchio&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/medionline_farmaci/55fbc366e0beb63e08ffc35e56e44242.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Fampyra migliora la mobilità nella sclerosi multipla&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/17/farmaci-news-2.html</guid>
                <title>Farmaci News (2)</title>
                <link>http://xagena.myblog.it/archive/2012/03/17/farmaci-news-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 17 Mar 2012 13:26:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmaci_it_news/b817f8dad313f809b7e71a53e14a9231.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Schizofrenia: i farmaci antipsicotici di seconda generazione hanno proprietà molto diverse tra loro &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmaci_it_news/b400f98a2d7ae72b97cb87a354ebfb9f.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Bevacizumab nel trattamento del glioblastoma multiforme &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmaci_it_news/bb91b5e0c0d06915055e3f03d6bc3816.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Farmaci oncologici: inibitori del VEGF, Bevacizumab&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmaci_it_news/0b61e0b51eb2377cb824c8bb24dab3c0.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Revisione della sicurezza dei farmaci che abbassano il colesterolo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-farmaci_it_news/4afa2aea8aa76eddf65a3b2c12a8f5f6.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Farmaci per il disturbo ADHD: problemi di sicurezza per Ritalin&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/17/cardiologia-news-2.html</guid>
                <title>Cardiologia News (2)</title>
                <link>http://xagena.myblog.it/archive/2012/03/17/cardiologia-news-2.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Sat, 17 Mar 2012 12:38:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-cardiologia_it_news/2e629be3103cf3cdfb7c163870d3e54d.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Terapia con defibrillatore impiantabile nei pazienti a rischio di morte cardiaca improvvisa &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-cardiologia_it_news/98a9e02cbbd5cfd0869534f8a0737ff5.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;Trombocitopenia nei pazienti con sindrome coronarica acuta, ma solo una piccola frazione è causata dall'Eparina&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-cardiologia_it_news/6df53cef666327a334686e16b14d0faa.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;Dislipidemia mista: l’insufficienza renale cronica può essere un fattore di rischio per la rabdomiolisi associata ai fibrati&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-cardiologia_it_news/a00932afc9f4deb1507c4be9835fb12e.html&quot;&gt;&lt;span style=&quot;color: #ff0000;&quot;&gt;La lattazione per lungo periodo riduce il rischio di malattia coronarica &lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;&lt;div class=&quot;listSpace&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;listTitoloB&quot;&gt;&lt;ul&gt;&lt;li&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;a href=&quot;http://www.xagena.it/news/e-cardiologia_it_news/fb56db5736e9e08a951803b8f72e9e6c.html&quot;&gt;&lt;span style=&quot;color: #0000ff;&quot;&gt;L'FDA ha approvato un nuovo inibitore dell'HMG-CoA reduttasi: Livalo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/16/neurologia-news.html</guid>
                <title>Neurologia News</title>
                <link>http://xagena.myblog.it/archive/2012/03/16/neurologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Fri, 16 Mar 2012 01:14:00 +0100</pubDate>
                <description>
                    &lt;h2 class=&quot;ecxpost-title&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; margin: 0px 0px 5px; font: 22px/24px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #006e12 !important; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 27px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologia.net/index.php?cat=farmaci&amp;amp;view=18283&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Laquinimod riduce le recidive e rallenta la disabilità nella sclerosi multipla recidivante-remittente&amp;nbsp;&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;p class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/p&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;I risultati di uno studio di fase III, randomizzato, hanno mostrato che Laquinimod ha ridotto i tassi di recidiva annualizzata, ha ritardato la progressione della disabilità, e ha diminuito l'attività di malattia al neuroimaging, rispetto al placebo.Il farmaco è risultato sicuro e ben tollerato, con bassa frequenza complessiva di eventi avversi, paragonabile al placebo. [...]&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologia.net/index.php?view=18283&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&amp;nbsp;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologia.net/index.php?view=18284&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Prevenzione dell’ictus nei pazienti con stenosi intracranica: interrotto lo studio SAMMPRIS a causa di un maggior rischio di ictus e di mortalità nel gruppo stent&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Il National Institute of Neurological Disorders and Stroke ( NINDS ) ha interrotto l’arruolamento in uno studio clinico che stava valutando I benefici aggiuntivi, rispetto alla sola terapia medica aggressiva, dell’angioplastica intracranica con stenting nella prevenzione dell’ictus nei pazienti con stenosi intracranica sintomatica.SAMMPRIS ( Stenting and Aggressive Medical [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.neurologia.net/?view=18284&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 27px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.sclerosionline.net/index.php?view=18299&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Cardiotossicità e altri eventi avversi associati a Mitoxantrone nel trattamento della sclerosi multipla&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 23px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 21px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Mitoxantrone ( Novantrone ) è utilizzato per la sclerosi multipla aggressiva, ma ci sono dubbi sulla sicurezza di questo farmaco. inclusa la cardiotossicità e altre misure di laboratorio.Uno studio ha valutato l’incidenza e i potenziali predittori di eventi avversi associati a Mitoxantrone in una clinica per la sclerosi multipla in Canada, con un’analisi di revisione retros [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.sclerosionline.net/?view=18299&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                        <item>
                <guid isPermaLink="true">http://xagena.myblog.it/archive/2012/03/14/infettivologia-news.html</guid>
                <title>Infettivologia News</title>
                <link>http://xagena.myblog.it/archive/2012/03/14/infettivologia-news.html</link>
                <author>noreply@myblog.it (xagenamedicina)</author>
                                                <category>Medicina</category>
                                                <pubDate>Wed, 14 Mar 2012 00:17:00 +0100</pubDate>
                <description>
                    &lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.herpesonline.net/index.php?cat=farmaci&amp;amp;view=12725&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Terapia soppressiva con Valaciclovir nell’herpes genitale di stadio iniziale&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;La terapia soppressiva non è stata valutata durante il primo anno dalla contrazione dell’herpes genitale, il tempo di massima frequenza di riattivazione, con potenzialità di trasmissione ed impatto sulla qualità della vita. Uno studio, compiuto da Ricercatori dell’University of Washington, a Seattle negli Stati Uniti, ha valutato l’efficacia della terapia soppressiva con Valac [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.herpesonline.net/index.php?view=12725&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;widows: 2; text-transform: none; background-color: #ffffff; text-indent: 0px; font: 13px/17px Tahoma, Verdana, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #2a2a2a; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.infettivologia.net/index.php?cat=farmaci&amp;amp;view=17396&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;La profilassi antibiotica per la leptospirosi&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;L’infezione da Leptospira è una zoonosi con un significativo impatto sanitario per i lavoratori agricoli e per le persone che per lavoro o per svago si trovano in aree endemiche. E’ stata svolta una revisione sistematica della letteratura per valutare le evidenze a favore o contro l'uso della profilassi antibiotica nell’infezione da Leptospira ( leptospirosi ). [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.infettivologia.net/?view=17396&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.herpesonline.net/index.php?view=9159&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;L’infezione primaria da herpesvirus-6 è generalmente sintomatica nell’infanzia&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Studi hanno indicato che l’herpesvirus-6 ( HHV-6 ) umano infetta il 90% dei bambini di 2 anni di etàTuttavia ci sono poche conoscenze riguardo a come venga acquisita l’infezione da HHV-6, al decorso virologico e alle manifestazioni cliniche.Lo studio prospettico ha riguardato una coorte di 277 bambini, seguiti dalla nascita [...]&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;font-size: medium;&quot;&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.herpesonline.net/?view=9159&amp;amp;page=1&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;div class=&quot;ecxpost&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;span style=&quot;font-size: large;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 28px; color: #006e12 !important; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.infettivologia.net/index.php?cat=farmaci&amp;amp;page=2&amp;amp;view=16905&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial;&quot;&gt;Antibiotici e antisettici per ulcere venose delle gambe&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/h2&gt;&lt;h2 class=&quot;ecxpost-title&quot; style=&quot;line-height: 24px; margin: 0px 0px 5px; color: #006e12 !important; font-size: 22px; font-weight: normal;&quot;&gt;&lt;strong&gt;&lt;/strong&gt;&amp;nbsp;&lt;/h2&gt;&lt;div class=&quot;ecxpost-content&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Le ulcere venose delle gambe sono un tipo di ferita cronica che colpisce fino al 1% degli adulti nei Paesi sviluppati in un momento della loro vita.La maggior parte di queste ferite sono colonizzate da batteri o mostrano segni di infezione clinica e la presenza di infezioni potrebbe ritardare la guarigione delle ferite.Per prevenire e trattare l’infezione clinica ne [...]&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&lt;span style=&quot;font-size: small;&quot;&gt;&lt;strong&gt;&lt;a style=&quot;line-height: 17px; color: #0068cf; cursor: pointer; text-decoration: underline;&quot; href=&quot;http://www.infettivologia.net/index.php?view=16905&amp;amp;page=2&quot; target=&quot;_blank&quot;&gt;&lt;span style=&quot;line-height: normal; font-family: Arial; font-size: medium;&quot;&gt;Leggi articolo completo&lt;/span&gt;&lt;/a&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div class=&quot;ecxpost-more&quot; style=&quot;line-height: 17px;&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
                </description>
                            </item>
                </channel>
</rss>
